Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

27
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
27
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

290
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
290
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

277
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
277
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

468
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
468
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

830
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
830
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

578
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
578

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Interactive Pharmacokinetic-Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Blood-glucose Profile Evaluation with a Model-based Approach using Continuous Glucose Monitoring Data.

The AAPS journal·2026
Same author

Glucose-dependent dynamics of glucagon, cortisol and adrenocorticotropic hormone before and after gastric bypass.

Journal of the Endocrine Society·2026
Same author

Association of Torque Teno Virus DNA Load and Tacrolimus in Peripheral Blood Mononuclear Cells of Adult Kidney Transplant Patients.

Therapeutic drug monitoring·2026
Same author

Learning Covariate Relations in Disease Progression Models Using Symbolic Neural Networks.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.

The Journal of antimicrobial chemotherapy·2026

Related Experiment Video

Updated: Feb 22, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K

Modeling sleep data for a new drug in development using markov mixed-effects models.

Maria C Kjellsson1, Daniele Ouellet, Brian Corrigan

  • 1Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden. maria.kjellsson@farmbio.uu.se

Pharmaceutical Research
|June 18, 2011
PubMed
Summary

This study used advanced modeling to analyze sleep patterns in insomnia patients treated with PD 0200390 and zolpidem. An accelerated approach effectively characterized drug effects on sleep architecture.

More Related Videos

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

6.1K
Noninvasive, High-throughput Determination of Sleep Duration in Rodents
07:33

Noninvasive, High-throughput Determination of Sleep Duration in Rodents

Published on: April 18, 2018

8.3K

Related Experiment Videos

Last Updated: Feb 22, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K
A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice
06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

6.1K
Noninvasive, High-throughput Determination of Sleep Duration in Rodents
07:33

Noninvasive, High-throughput Determination of Sleep Duration in Rodents

Published on: April 18, 2018

8.3K

Area of Science:

  • Pharmacology
  • Sleep Medicine
  • Biostatistics

Background:

  • Insomnia significantly impacts sleep quality and daily functioning.
  • Understanding the time-course and concentration-effect relationships of hypnotics is crucial for optimizing treatment.
  • Existing models may not fully capture the dynamic nature of sleep stages and drug effects.

Purpose of the Study:

  • To characterize the temporal dynamics of sleep in insomnia patients.
  • To evaluate the concentration-effect relationships of PD 0200390 and zolpidem.
  • To implement an accelerated mixed-effects Markov model strategy for sleep analysis.

Main Methods:

  • Utilized data from a Phase II clinical study involving five treatment conditions.
  • Employed first-order Markov models, developed sequentially for baseline, placebo, and drug conditions.
  • Incorporated predefined models and accounted for inter-subject and inter-occasion variability to accelerate model building.

Main Results:

  • Baseline sleep patterns were described using piecewise linear models influenced by time and sleep stage duration.
  • Placebo primarily affected light sleep stages, while both PD 0200390 and zolpidem impacted slow-wave sleep.
  • Simulations indicated that administering PD 0200390 30 minutes earlier reduced latency to persistent sleep by 40%.

Conclusions:

  • The accelerated model-building strategy effectively described sleep patterns in insomnia patients.
  • The developed models provide insights into the time-course and concentration-effect relationships of hypnotic agents.
  • This approach offers a robust method for analyzing complex sleep data in clinical trials.